Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Healthcare.
Press releases published on May 20, 2025
Sierra Tucson Receives National Fraternal Order of Police Recognition
GlobeNewswire
·
May 20, 2025
TUCSON, Ariz., May 20, 2025 (GLOBE NEWSWIRE) -- Sierra Tucson, one of the country’s leading behavioral health treatment centers, announced that its Red, White and Blue program has been officially recognized and approved by the National Fraternal Order of …
Tunnel to Towers Foundation Adds Rutgers, Penn State-Behrend Athletes to Growing NIL Program
GlobeNewswire
·
May 20, 2025
Staten Island, NY, May 20, 2025 (GLOBE NEWSWIRE) -- The Tunnel to Towers Foundation today announced the expansion of its T2T Student-Athlete Advocate Program, adding two new students to the growing initiative designed to connect current student-athletes to …
Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
May 20, 2025
– Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in …
Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
GlobeNewswire
·
May 20, 2025
SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Natural Remedies Introduces Ashwa.30, a Next-Gen Ashwagandha for Energy, Endurance and Stress Support
GlobeNewswire
·
May 20, 2025
BANGALORE, India, May 20, 2025 (GLOBE NEWSWIRE) -- Natural Remedies, a global leader in botanical branded ingredients, announces the launch of Ashwa.30, a next-generation ashwagandha extract designed to improve energy, boost endurance, and support stress …
中国患者越来越多的JY整形外科皮肤科扩大韩中美容医疗交流
EIN Presswire
·
May 20, 2025
对Ulthera·钛提拉术、皮肤助推器等高功能施术的需求增加 继中国医疗团队访问之后, 正式开始交流, 确认K-美容的地位 SEOUL, GANGNAM, SOUTH KOREA, May 20, 2025 /EINPresswire.com/ -- 位于首尔清潭洞的JY整形外科皮肤科继中国医疗团队的正式访问之后, 当地患者也接连访问, 作为韩中美容医疗交流的中心备受关注。 据JY整形外科皮肤科透露, 最近中国患者的访问次数不断增加, 特别是对Ulthera …
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal
GlobeNewswire
·
May 20, 2025
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
aTyr Pharma to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 20, 2025
SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that …
Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis
GlobeNewswire
·
May 20, 2025
NIJMEGEN, the Netherlands, May 20, 2025 (GLOBE NEWSWIRE) -- Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has enrolled the first patient in a Phase 1/2 clinical …
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
GlobeNewswire
·
May 20, 2025
- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo - In the …
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
GlobeNewswire
·
May 20, 2025
Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone provides 10 years of market exclusivity in Europe upon approval ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. …
BriaCell CEO Letter to Shareholders
GlobeNewswire
·
May 20, 2025
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitor Bria-IMT has received Fast Track designation from FDA and patient enrollment …
Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy after Dose Escalation Decision by Safety Review Committee
GlobeNewswire
·
May 20, 2025
TUS+VEN+AZA triplet achieves complete remissions (CRs) and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients Completed 40 mg and 80 mg TUS dose cohorts; no prolonged myelosuppression or dose-limiting toxicities …
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease
GlobeNewswire
·
May 20, 2025
– Rapid, deep, and durable reductions in high-sensitivity C-reactive protein (hs-CRP) through Day 90 achieved across all pacibekitug arms with high statistical significance as compared to placebo (p<0.0001 for all arms) – – Pacibekitug becomes the first …
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
GlobeNewswire
·
May 20, 2025
- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an …
I-Mab to Present at Jefferies Global Healthcare Conference
GlobeNewswire
·
May 20, 2025
ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management …
Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic
GlobeNewswire
·
May 20, 2025
The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic …
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
GlobeNewswire
·
May 20, 2025
Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass, cardiac protection and bone mineral density in obese …